About the Study
The PAPR Study includes participating sites in Massachusetts, Delaware, North Carolina, South Carolina, Ohio, Tennessee, Utah, Texas, Arizona, California, and Oregon. Blood samples were prospectively collected from pregnant women between 17 and 28 weeks of gestation. All specimens are well-characterized based on delivery outcomes and both maternal and neonatal health. Sera's test is expected to measure concentrations of multiple protein biomarkers across several functional pathways that are relevant to preterm birth.
About Preterm Birth
Of the 4 million babies born annually in the U.S., approximately one in eight, or 12 percent, is born preterm. Preterm birth is the leading cause of illness and death in newborns and is associated with a significantly increased risk of major long-term medical complications, including learning disabilities, cerebral palsy, chronic respiratory illness, intellectual disability, seizures, and vision and hearing loss. A study published in 2006 by the Institute of Medicine and the March of Dimes reported that total costs incurred in the U.S. for treating complications of preterm birth exceed $26 billion each year. The complications from preterm birth also extend beyond the first year of life, and generate significant costs throughout the lives of affected children.
About Sera Prognostics, Inc.
Sera Prognostics is a private biotechnology company developing innovative diagnostic tests designed for the early prediction of preterm birth and other pregnancy complications. Sera's tests are designed to help better inform the care of a mother and her unborn child during pregnancy, and potentially lead to improved health. In November 2011, the company completed a Series A financing round of $19.3 million to develop its preterm birth predictor. The company has assembled a strong management team and Board of Directors with significant clinical development and women's healthcare diagnostic experience. Sera is located in Salt Lake City, Utah. For more information, please visit the company's website at www.seraprognostics.com.
CONTACT: Company Contact:
Andrew Sauter, CFO
Sera Prognostics, Inc.email@example.com
Media Contact for Sera Prognostics:
Terri ClevengerContinuum Health Communicationstclevenger@continuumhealthcom.com
Source: Sera Prognostics, Inc.